ストックスクリーナーアプリを入手
8.18
0.12%
-0.010
アフターアワーズ：
8.18
前日終値:
$8.19
開ける：
$8.16
24時間の取引高:
577.23K
Relative Volume:
0.27
時価総額：
$3.01B
収益：
$9.47B
当期純損益:
$-178.00M
株価収益率:
-3.0985
EPS:
-2.64
ネットキャッシュフロー:
$1.01B
1週間 パフォーマンス:
-6.62%
1か月 パフォーマンス:
+0.12%
6か月 パフォーマンス:
+24.89%
1年 パフォーマンス:
+18.38%
1日の値動き範囲:
$8.11
$8.215
1週間の範囲:
$8.11
$8.73
52週間の値動き範囲:
$3.96
$11.46
Bausch Health Companies Inc Stock (BHC) Company Profile
名前
Bausch Health Companies Inc
セクター
電話
514-744-6792
住所
2150 ST. ELZEAR BLVD. WEST, QUEBEC, QC
BHC を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
| BHC | 8.18 | 3.01B | 9.47B | -178.00M | 1.01B | -2.64 |
| ZTS | 176.71 | 79.55B | 9.15B | 2.43B | 2.31B | 4.92 |
| HLN | 9.55 | 43.18B | 14.26B | 1.55B | 0 | 0.3327 |
| TAK | 13.33 | 42.26B | 30.27B | 1.93B | 3.45B | 0.444 |
| TEVA | 17.08 | 19.35B | 16.77B | -959.00M | 1.37B | -2.00 |
| VTRS | 13.25 | 15.77B | 15.24B | -646.50M | 1.88B | 1.53 |
Bausch Health Companies Inc Stock (BHC) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2023-09-20 | アップグレード | Jefferies | Hold → Buy |
| 2023-06-16 | ダウングレード | TD Cowen | Outperform → Market Perform |
| 2022-07-29 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-07-29 | ダウングレード | Truist | Buy → Hold |
| 2022-07-28 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2022-06-13 | 再開されました | JP Morgan | Overweight |
| 2021-03-24 | ダウングレード | BofA Securities | Neutral → Underperform |
| 2021-02-17 | アップグレード | RBC Capital Mkts | Sector Perform → Outperform |
| 2021-01-22 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2020-09-17 | アップグレード | BofA Securities | Underperform → Neutral |
| 2020-08-24 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-06-17 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-04-24 | 開始されました | Citigroup | Buy |
| 2020-04-02 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2020-01-29 | ダウングレード | Wolfe Research | Outperform → Peer Perform |
| 2020-01-22 | アップグレード | Wells Fargo | Underweight → Equal Weight |
| 2019-12-12 | アップグレード | JP Morgan | Neutral → Overweight |
| 2019-12-02 | 開始されました | Goldman | Neutral |
| 2019-10-25 | 開始されました | Cowen | Outperform |
| 2019-09-12 | 開始されました | Guggenheim | Buy |
| 2019-08-15 | アップグレード | TD Securities | Hold → Buy |
| 2019-07-19 | 開始されました | Wolfe Research | Outperform |
| 2019-06-11 | 再開されました | Barclays | Overweight |
| 2019-05-13 | アップグレード | JP Morgan | Underweight → Neutral |
| 2019-03-20 | 開始されました | SunTrust | Buy |
| 2019-01-02 | アップグレード | Piper Jaffray | Neutral → Overweight |
| 2018-11-05 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2018-09-13 | アップグレード | Piper Jaffray | Underweight → Neutral |
すべてを表示
Bausch Health Companies Inc (BHC) 最新ニュース
Aesthetic Devices Market in Mexico to Grow by USD 533.06 Million (2024-2028) as AI Impacts Market Trends, Rising Awareness Boosts RevenueTechnavio - Lelezard
LMR Partners LLP Purchases Shares of 400,000 Bausch Health Companies Inc. (NYSE:BHC) - MarketBeat
US Supreme Court declines to hear patent dispute over Bausch blockbuster diarrhea drug - Marketscreener.com
Herpes Zoster Oticus Market: Company Profiles, Segment Sizes, - openPR
Bausch Health and Salix to Present at the American Association for the Study of Liver Disease (AASLD) the RED-C Phase 3 Study Design for a New Investigational Product Designed to Address Serious Complications of Cirrhosis - AccessWire
Bausch Health's Triple-Action Acne Treatment CABTREO Gains Key Canadian Approvals | BHC Stock News - StockTitan
Common Warts Treatment Market Trade Analysis and Statistical - openPR
Underactive Bladder Treatment Market Expected to Reach Huge - openPR
Genital Herpes Treatment Market Global Share, Trends, Business - openPR
Varicella Zoster (HHV-3) Infections Treatment Market Share, - openPR
Vitrectomy Devices Market is expected to reach US$ 2121.3 - openPR
22q11.2 Deletion Syndrome Market Forecasted to Surge in Coming Years, 2024-2034 Analysis by DelveInsight | Nobias Therapeutics, Zynerba Pharma, Bausch Health Americas - The Globe and Mail
Actinic Keratosis Market Growth to Accelerate in Forecast Period (2023-2032), DelveInsight Analyze | Bausch Health Companies, Sandoz Pharma, Athenex, Almirall, Vidac Pharma, G&E Herbal Biotech - Barchart
Periodontal Therapeutics Market to Grow at a Promising CAGR - openPR
Bausch Health Companies: Top 25 Undervalued Toronto Stock Exchange Stocks (BHC) - Barchart
Myopia and Presbyopia Treatment Market to Grow by USD 9.76 Billion from 2024-2028, as Rising Prevalence Drives Demand with AI Redefining Market LandscapeTechnavio - The Malaysian Reserve
Are Medical Stocks Lagging Bausch Health (BHC) This Year? - MSN
Body Contouring Treatments Market to Hit USD 2.58 Billion by 2029 with 10.0% CAGR | MarketsandMarkets™ - The Manila Times
Eye Health Supplements Market Trends and Growth Projections - openPR
Gastroparesis Drugs Market to Grow by USD 1.42 Billion from 2024-2028, Driven by Rising Diabetes Rates and AI-Driven Market Trend InsightsTechnavio - The Malaysian Reserve
189,000 Shares in Bausch Health Companies Inc. (NYSE:BHC) Bought by Intact Investment Management Inc. - MarketBeat
Bausch Health Companies' SWOT analysis: debt woes cloud strong Q3 stock performance - Investing.com
Why Bausch Health (BHC) is a Top Momentum Stock for the Long-Term - Yahoo Finance
Bausch Health Q3 Earnings and Revenues Top, Xifaxan Boosts Sales - MSN
Bausch Health Companies Inc. (NYSE:BHC) Given Consensus Recommendation of "Hold" by Analysts - MarketBeat
Bausch Health secures $400 million loan amendment - Investing.com
Bausch Health secures $400 million loan amendment By Investing.com - Investing.com UK
Bausch Health Companies (NYSE:BHC) Price Target Raised to $11.00 at Royal Bank of Canada - MarketBeat
Bausch Health Companies Inc. (NYSE:BHC) Q3 2024 Earnings Call Transcript - Insider Monkey
Bausch Health Companies Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags - Simply Wall St
Bausch Health stock outlook lifted as RBC cites robust Q3 growth and tax benefits - Investing.com
Traders Purchase High Volume of Bausch Health Companies Put Options (NYSE:BHC) - MarketBeat
Toronto Stocks Drop, Canada's GDP Flat in August; Bausch Health Rises on 3Q Beat - Marketscreener.com
Bausch Health Shares Rise on FY Outlook Upgrade, 3Q Beat - MarketWatch
Bausch Health Companies (NYSE:BHC) Trading 8.7% Higher on Better-Than-Expected Earnings - MarketBeat
Bausch Health Companies (TSE:BHC) Stock Price Up 8.4% Following Earnings Beat - MarketBeat
BHCBausch Health Companies Inc. Latest Stock News & Market Updates - StockTitan
Bausch: Q3 Earnings Snapshot - Houston Chronicle
Bausch Health Reports Growth Amid Improved Financials - TipRanks
Compared to Estimates, Bausch (BHC) Q3 Earnings: A Look at Key Metrics - Yahoo Finance
Bausch Health (BHC) Beats Q3 Earnings and Revenue Estimates - Yahoo Finance
Bausch Health Companies Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Bausch Health Announces Third Quarter 2024 Results - AccessWire
Gastroparesis Treatment Market Top Trends and Growth Analysis: - openPR
Bausch Health Companies Q3 2024 Earnings Preview - MSN
Onychomycosis Treatment Market Size, Industry Analysis, - openPR
Actinic Keratosis Treatment Market Expected to Reach Huge - openPR
Canada Aesthetic Devices Market Size, Share, Industry Growth, - openPR
Bausch Health Companies Inc. and Salix Pharmaceuticals Announce Results of an Analysis of Xifaxan Monotherapy Will Be Presented During A Presidential Plenary Session of the American College of Gastroenterology 2024 Annual Scientific Meeting Taking - Marketscreener.com
ACG Presidential Plenary to Highlight Analysis of Xifaxan(R) (rifaximin) Risk Reduction of Overt Hepatic Encephalopathy (OHE) Recurrence - StockTitan
TD COWEN Downgrades Bausch Health Companies (BHC) - MSN
Bausch Health Companies Inc (BHC) 財務データ
収益
当期純利益
現金流量
EPS
1.01%
0.30%
大文字化:
|
ボリューム (24 時間):